Ignite Creation Date:
2024-05-06 @ 2:15 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04269954
Status:
UNKNOWN
Last Update Posted:
2020-02-17
First Post:
2020-02-12
Brief Title:
The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis
Sponsor:
Capital Medical University
Organization:
Capital Medical University
Study Overview
Official Title:
The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis
Status:
UNKNOWN
Status Verified Date:
2020-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Our previous clinical case observations showed that batroxobin combined with anticoagulation therapy can improve the sinus recanalization rate in patients with CVST shorten the hospital stay and increase the neurological score of patients Its main mechanism is to inhibit thrombosis after reducing fibrinogen and to dissolve thrombus
To further explore the safety of batroxobin combined with anticoagulation therapy for CVST an open-label randomized controlled 1 1 single-center prospective study was used Further study on the safety and effectiveness of batroxobin combined with anticoagulation for CVST
To further explore the safety of batroxobin combined with anticoagulation therapy for CVST an open-label randomized controlled 1 1 single-center prospective study was used Further study on the safety and effectiveness of batroxobin combined with anticoagulation for CVST
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None